Abstract
In response to three reports of an association between rauwolfia derivatives and breast cancer, a case/control study was undertaken in Olmsted County, Minnesota. Comparison of a cohort of women with breast cancer to an age-matched cohort of women with cholelithiasis failed to show any meaningful differences in the two groups except with respect to a history of hypertension. The rates of use of rauwolfia derivatives by hypertensive cases and controls were identical-which, along with other considerations, leads to the conclusion that an association between the use of rauwolfia derivatives and breast cancer is unlikely.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 292-296 |
| Number of pages | 5 |
| Journal | The Lancet |
| Volume | 306 |
| Issue number | 7929 |
| DOIs | |
| State | Published - Aug 16 1975 |
Funding
This work was supported by National Cancer Institute post-doctoral fellowship 1 F22 CA-2204-01 (W. M. O’F.), and by Program Project grant the National Institutes of Health, U.S. Public Health Service. We thank Dr Kenneth G. Berge for help in identifying the antihypertensive agents, Elvera Cordes, Sheila McNallan, and Ann Ryan for the abstracting, and LaDonna Corbin and Evelyn Pochardt for assistance in manuscript preparation. Requests reprints should be addressed to D. R. L.
ASJC Scopus subject areas
- General Medicine
